Journal
Crohn's & Colitis 360
Publication Date
7-1-2023
Volume
5
Issue
3
First Page
otad022
Document Type
Open Access Publication
DOI
10.1093/crocol/otad022
Rights and Permissions
Suha Abushamma, MD and others, Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study, Crohn's & Colitis 360, Volume 5, Issue 3, July 2023, otad022, https://doi.org/10.1093/crocol/otad022. https://academic.oup.com/crohnscolitis360/article/5/3/otad022/7148845?login=true. © The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Abushamma, Suha; Walker, Ted; Garza, Kevin; Chen, Ling; Nix, Darren; and Chen, Chien-Huan, "Accelerated infliximab infusion safety and tolerability is non-inferior to standard infusion protocol in inflammatory bowel disease patients: A randomized controlled study." Crohn's & Colitis 360. 5, 3. otad022 (2023).
https://digitalcommons.wustl.edu/oa_4/1864
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
